AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05958719
Drug: Chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: chidamide 30mg biw, p.o, 21 days for a cycle.
Trial: NCT05958719
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 75mg/m2, continuous i.h. on day 1-7，21 days for a cycle.
Trial: NCT05958719
Drug: liposomal mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12mg/m2， d1,21 days for a cycle.
Trial: NCT05958719
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60mg/m2，d1-5,21 days for a cycle.
Trial: NCT05826912
Drug: Atorvastatin Calcium
RxNorm normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule, 80 mg/day, with no loading dose, for 28 days
Trial: NCT05826912
Drug: Candesartan Cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsule, 8 mg once on Day 1, then 16 mg daily for 27 days
Trial: NCT06462118
Drug: Astegolimab
RxNorm normalized name: Astegolimab
DrugBank: Astegolimab (DB16386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one SC dose of astegolimab in the abdomen, upper arm, or thigh.
Trial: NCT05595460
Drug: RYZ101 Dose Level 1
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Level 1
Trial: NCT05595460
Drug: RYZ101 Dose Level 2
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Level 2
Trial: NCT05595460
Drug: RYZ101 Dose Level 3
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Level 3
Trial: NCT05595460
Drug: RYZ101 Dose Level -1
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Level -1
Trial: NCT05595460
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab
Trial: NCT05595460
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin
Trial: NCT05595460
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide
Trial: NCT05151549
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg/3weeks
Trial: NCT05151549
Drug: Cisplatin or Carboplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
Trial: NCT06352723
Drug: Cenobamate
RxNorm normalized name: Cenobamate
DrugBank: Cenobamate (DB06119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Study Drug: Cenobamate 400mg x 1 NGT/G-tube (Day 1), 100mg (Day 2-14)~* Discontinued cenobamate upon cessation of seizures or RegiSCAR score 4-5 or at 14 days.~* Adjust cenobamate dose based on patient response; this may include discontinuation if seizures resolve, or increase in dose to 150mg or 200mg a day after Day 7
Trial: NCT06779929
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tirzepatide
Trial: NCT06779929
Drug: Dulaglutide
RxNorm normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dulaglutide
Trial: NCT05060003
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab is provided by Genentech.
Trial: NCT05060003
Drug: Tiragolumab
RxNorm normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiragolumab is provided by Genentech.
Trial: NCT06247917
Drug: Fludarabine, Busulfan and Melphalan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Use Fludarabine, Busulfan and Melphalan as myeloablative conditioning regimen for untreated MDS-EB patients.
Trial: NCT05139680
Drug: tafamidis
RxNorm normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 or 61 milligrams (mg)
Trial: NCT06510660
Drug: adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study was divided into two cohorts based on CPS score, with those with CPS scores ≥10 receiving induction therapy with adebrelimab alone and those with CPS scores \<10 receiving induction therapy with adebrelimab in combination with chemotherapy. At the end of the induction period, concurrent radiotherapy treatment was administered
Trial: NCT05062174
Drug: Mifepristone 200 MG
RxNorm normalized name: mifepristone 200 MG
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally, one time dosage of 200 mg
Trial: NCT04589845
Drug: Entrectinib
RxNorm normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adults and pediatric participants with a BSA \>/= 1.51 m2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m2) or 300 mg/day (BSA=0.81-1.10 m2) or 200 mg/day (BSA=0.51-0.80 m2) or 100 mg/day (BSA=0.43-0.50 m2).
Trial: NCT04589845
Drug: Alectinib
RxNorm normalized name: Alectinib
DrugBank: Alectinib (DB11363)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Alectinib will be administered orally BID (twice a day) with food at a dosage of 600 mg (four 150-mg capsules).
Trial: NCT04589845
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg for participants aged \>/=18 years, and 15 mg/kg (maximum 1200 mg) for participants aged \<18 years on Day 1 of each 21-day cycle.
Trial: NCT04589845
Drug: Ipatasertib
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants \< 35 kg, 300 mg for participants \>/= 35 and \< 45 kg, 400 mg for those \>/= 45 kg orally QD, beginning of Cycle 1, on Days 1-21 of each 28-day cycle until the participant experiences disease progression, intolerable toxicity, or withdraws consent.
Trial: NCT04589845
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab emtansine will be administered at 3.6 mg/kg by IV infusion every 21 days until disease progression or unacceptable toxicity. The dosage and administration method also applies for pediatric participants 12-17 years of age.
Trial: NCT04589845
Drug: Idasanutlin
RxNorm normalized name: Idasanutlin
DrugBank: Idasanutlin (DB12325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idasanutlin will be administered at 250 mg QD (daily) PO for Days 1-5 of each 28-day cycle. Idasanutlin may be given without regard to meals and water can be given as often as necessary or desired. The daily doses should be administered 10-14 hours apart.~Note: Cohort G has been closed for enrollment.
Trial: NCT04589845
Drug: Inavolisib
RxNorm normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-077 will be administered QD at a starting dose of 9 mg PO in repeated 28-day cycles. The dosage and administration method also applies for pediatric participants 12-17 years of age.
Trial: NCT04589845
Drug: Belvarafenib
RxNorm normalized name: Belvarafenib
DrugBank: Belvarafenib (DB17568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belvarafenib will be administered at a dose 400 mg (PO) BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.
Trial: NCT04589845
Drug: Pralsetinib
RxNorm normalized name: pralsetinib
DrugBank: Pralsetinib (DB15822)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pralsetinib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric patients ≥ 12 and \< 18 years of age. A treatment cycle consists of 4 weeks (28 days).
Trial: NCT04589845
Drug: GDC-6036
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC-6036 will be self-administered by patients orally at home (except on clinic days) on a continuous daily dosing regimen for both adult and pediatric patients. A treatment cycle consists of 3 weeks (21 days).
Trial: NCT00001126
Drug: Cidofovir
RxNorm normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04589845
Drug: Camonsertib
RxNorm normalized name: Camonsertib
DrugBank: Camonsertib (DB18888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camonsertib will be self-administered by patients orally at home (except on clinic days). A treatment cycle consists of 3 weeks and will be given on days 1-3 and days 8-10 of every 21-day cycle.
Trial: NCT05543603
Drug: Lacer Clorhexidina Colutorio
RxNorm normalized name: Clorhexidina
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 ml 0,12% Chlorhexidine, one minute rinse
Trial: NCT05543603
Drug: Distilled water
RxNorm normalized name: Distilled Water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml distilled water, one minute rinse
Trial: NCT05488873
Drug: WST-057 Active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WST-057 Topical Solution
Trial: NCT06357182
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC
Trial: NCT06357182
Drug: Iadademstat
RxNorm normalized name: Iadademstat
DrugBank: ORY-1001 (DB16848)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06357182
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04322383
Drug: binimetinib
RxNorm normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.
Trial: NCT06703177
Drug: SHR-1826
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1826
Trial: NCT06703177
Drug: SHR-4642
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-4642
Trial: NCT06703177
Drug: SHR-9839
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-9839
Trial: NCT06703177
Drug: SHR-8068
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-8068
Trial: NCT06703177
Drug: Bevacizumab Injection
RxNorm normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab Injection
Trial: NCT06703177
Drug: Calcium Folinate Injection
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Calcium Folinate Injection
Trial: NCT06703177
Drug: Adebrelimab Injection
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab Injection
Trial: NCT04843566
Drug: Antibiotic (prophylaxis)
RxNorm normalized name: STONE PROPHYLAXIS
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy.
Trial: NCT04780568
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04780568
Drug: Tegavivint
RxNorm normalized name: Tegavivint
DrugBank: Tegavivint (DB17109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05906953
Drug: HG004
RxNorm normalized name: HG004
DrugBank: HG004 (DB18666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Medium dose High dose
Trial: NCT06299098
Drug: Trevogrumab-Part A
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Trevogrumab (DB15159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV or SC in Part A
Trial: NCT06299098
Drug: Trevogrumab-Part B and Part C
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Trevogrumab (DB15159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC in Part B, Part C
Trial: NCT06299098
Drug: Garetosmab
RxNorm normalized name: Garetosmab
DrugBank: Garetosmab (DB16379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV in Part B
Trial: NCT06204432
Drug: Sodium Citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Those randomized to the Sodium Citrate arm will use 1 mL of 2.5% sodium citrate (3.5g/140 mL, pH 7.4, 298 mOsmol/L), 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.
Trial: NCT00624741
Drug: Pergolide
RxNorm normalized name: Pergolide
DrugBank: Pergolide (DB01186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pergolide tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
Trial: NCT06299098
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC in Part B and Part C
Trial: NCT05154994
Drug: Belinostat
RxNorm normalized name: Belinostat
DrugBank: Belinostat (DB05015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06552234
Drug: Repotrectinib
RxNorm normalized name: Repotrectinib
DrugBank: Repotrectinib (DB16826)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repotrectinib 160 mg BID, until progression or unacceptable toxicity
Trial: NCT06299098
Drug: Matching Placebo-Trevogrumab
DrugBank: Trevogrumab (DB15159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC in Part B and Part C
Trial: NCT06299098
Drug: Matching Placebo-Garetosmab
DrugBank: Garetosmab (DB16379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV in Part B
Trial: NCT04932915
Drug: Niclosamide
RxNorm normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Niclosamide is a broad spectrum, host targeting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide solution is administered directly to the nasal cavity via a nasal spray.
Trial: NCT06222723
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone will be administered for 10 days. For the first 48 hours, dexamethasone will be given iv. After 48 hours, a switch to oral dexamethasone (same dosage) is permitted at the discretion of the study physician.
Trial: NCT06222723
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin treatment will be administered iv for 10 days, as recommended in the Nigeria Centre for Disease Control and Prevention National Guidelines for LF Case Management.
Trial: NCT06139575
Drug: Lutetium Lu 177 JH020002 Injection
RxNorm normalized name: lutetium Lu 177 dotatate Injection
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Lutetium Lu 177 JH020002 Injection every 6 weeks for a maximum of 6 doses. Doses range between 1.85 and 8.88 GBq (50-240 mCi)
Trial: NCT05198934
Drug: Sotorasib
RxNorm normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sotorasib will be administered orally
Trial: NCT05198934
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab will be administered as intravenous (IV) infusion
Trial: NCT05198934
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib will be administered orally
Trial: NCT06464055
Drug: Dose Expansion1
RxNorm normalized name: COOK MYOSITES AUTOLOGOUS MUSCLE DERIVED CELLS (AMDC) ARE EXPANDED (AMPLIFIED) THROUGH A TWO-PHASE MANUFACTURING PROCESS. THE EXPANSION IS CONSISTENT WITH ROUTINE CELL CULTURE PRACTICES FOR ADHERENT CELLS. DURING ADHERENT CELL CULTURE EXPANSION, CELLS REP
DrugBank: Iltamiocel (DB19059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: GQ1010 dose 1
Trial: NCT06464055
Drug: Dose Expansion2
RxNorm normalized name: COOK MYOSITES AUTOLOGOUS MUSCLE DERIVED CELLS (AMDC) ARE EXPANDED (AMPLIFIED) THROUGH A TWO-PHASE MANUFACTURING PROCESS. THE EXPANSION IS CONSISTENT WITH ROUTINE CELL CULTURE PRACTICES FOR ADHERENT CELLS. DURING ADHERENT CELL CULTURE EXPANSION, CELLS REP
DrugBank: Iltamiocel (DB19059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: GQ1010 dose 2
Trial: NCT06464055
Drug: Dose Expansion3
RxNorm normalized name: COOK MYOSITES AUTOLOGOUS MUSCLE DERIVED CELLS (AMDC) ARE EXPANDED (AMPLIFIED) THROUGH A TWO-PHASE MANUFACTURING PROCESS. THE EXPANSION IS CONSISTENT WITH ROUTINE CELL CULTURE PRACTICES FOR ADHERENT CELLS. DURING ADHERENT CELL CULTURE EXPANSION, CELLS REP
DrugBank: Iltamiocel (DB19059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: GQ1010 dose 3
Trial: NCT05673200
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT04685577
Drug: Nefopam
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam HCl inhibits the proliferation and viability of human mesenchymal fibroblasts with elevated β-catenin expression without affecting normal fibroblasts. Nefopam HCl primarily targets cells in which β-catenin is above normal physiologic levels. This threshold effect makes Nefopam HCl a good prospective therapeutic agent by limiting its effect to abnormal mesenchymal cells.Nefopam HCl has been found safe and effective for the reduction of dermal scarring following standardized human dermal wounds of critical depth that produces HTS in normal human volunteers Phase 1 study. In the current study, it is proposed that the concentration of the cream will be 3% and the timing of application will be delayed until after re-epithelialization at about 21 days to maximize the antiproliferative effects of NEFOPAM during the fibrotic/proliferative phase of healing.
Trial: NCT06694948
Drug: pimicotinib capsules
RxNorm normalized name: Pimicotinib
DrugBank: Pimicotinib (DB18972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pimicotinib capsules
Trial: NCT05846230
Drug: BI 1291583
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT05605548
Drug: MitoQ
RxNorm normalized name: Mitoquinone
DrugBank: Mitoquinone (DB05063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MitoQ is a mitochondrial targeted antioxidant that can be obtained over-the-counter.
Trial: NCT05502562
Drug: Oral semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
Trial: NCT05984121
Drug: Local ozon injections
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local ozone therapy is approximately 2-3 cc of medical ozone, ozone-resistant is realised by injecting subcutaneously or intramuscularly with injectors. Local ozone injection group at 0., 2. and 4. weeks with ultrasound guided medial Firstly 1.5 cc with a 25 gauge needle into the plantar fascia insertion in the plantar region 02 lidocaine injection in a sterile way and then (according to the weeks 3 cc ozone injection of 10, 15 and 20 pyg/ml will be made respectively.
Trial: NCT05984121
Drug: Local dextroz prolotherapy injections
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose prolotherapy injection group under ultrasound guidance at weeks 0, 2 and 4 1.5 cc 30% dextrose solution and 1.5 cc 2 lidocaine mixture with a 25 gauge needle into the medial plantar region cc 2 lidocaine mixture will be made sterile with 3 cc 15% dextrose.
Trial: NCT05407389
Drug: KT-301 (formerly US-APR2020)
RxNorm normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: KT-301 (formerly US-APR2020) will be administered orally at 2 capsules per day (a total dose of 90 Billion CFUs per day of the Live BioTherapeutic).